|
199 Companies |
|
329 Products |
|
329 Products |
|
164 Mechanisms of Action |
|
13 Trials |
|
3299 News |
|
| «12...678910111213141516...6768» |
- | NovoThirteen (catridecacog) / Novo Nordisk
Trial completion: Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency (clinicaltrials.gov) - Jan 10, 2017
P1, N=11, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed
- || Farydak (panobinostat) / Secura Bio
Trial primary completion date, Combination therapy: Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients (clinicaltrials.gov) - Jan 6, 2017
P1, N=77, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
No longer recruiting --> Completed Trial primary completion date: Feb 2018 --> Feb 2019
- Trial completion, Trial primary completion date: Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment. (clinicaltrials.gov) - Jan 5, 2017
P=N/A, N=82, Completed, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Feb 2018 --> Feb 2019 Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2016
- || carfilzomib / Generic mfg.
Clinical: A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols (clinicaltrials.gov) - Jan 5, 2017
P2, N=100, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2016 Trial primary completion date: Dec 2016 --> Mar 2017
- ||| BeneFix (nonacog alfa) / Pfizer
Trial completion, Trial primary completion date, Adverse events: Registry For Patients Treated With BeneFix In Usual Care Setting In Germany (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=100, Completed, Sponsor: Pfizer
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: Oct 2017 --> Oct 2016
- New trial: HeL-Fascial: Fascial Therapy in Elbow Hemophilic Arthropathy (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=60, Not yet recruiting, Sponsor: Real Fundación Victoria Eugenia
- ||| Enrollment open: Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass (clinicaltrials.gov) - Dec 30, 2016
P=N/A, N=60, Recruiting, Sponsor: Ume
Recruiting --> Completed | Trial primary completion date: Oct 2017 --> Oct 2016 Not yet recruiting --> Recruiting
- TevaGrastim (filgrastim biosimilar) / Nippon Kayaku, Teva, Mozobil (plerixafor) / Sanofi
Trial completion, Trial primary completion date, Combination therapy, Head-to-Head: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 23, 2016
P2, N=100, Completed, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2016
- New trial: Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=10, Not yet recruiting, Sponsor: Children's Hospital Los Angeles
- Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=400, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2016 Trial primary completion date: Jan 2017 --> Dec 2018
- Enrollment open: FEISTY: Fibrinogen Early In Severe Trauma studY (clinicaltrials.gov) - Dec 22, 2016
P2, N=100, Recruiting, Sponsor: Gold Coast Hospital and Health Service
Trial primary completion date: Jan 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Enrollment closed, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=23, Active, not recruiting, Sponsor: CSL Behring
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Darzalex (daratumumab) / J&J, Imfinzi (durvalumab) / AstraZeneca
New P2 trial: FUSION-MM-005: A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov) - Dec 22, 2016
P2, N=120, Not yet recruiting, Sponsor: Celgene Corporation
- | Empliciti (elotuzumab) / AbbVie, BMS, Decadron (dexamethasone) / Merck (MSD)
New P2 trial, IO biomarker: 2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy (clinicaltrials.gov) - Dec 22, 2016
P2, N=200, Not yet recruiting, Sponsor: University of Arkansas
- bortezomib / Generic mfg., melphalan / Generic mfg.
Trial primary completion date: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Dec 21, 2016
P1/2, N=11, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Oct 2017
- albumin-bound paclitaxel / Generic mfg.
Trial primary completion date: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 21, 2016
P2, N=13, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- Trial completion: GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=3706, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Completed
- Mozobil (plerixafor) / Sanofi
New trial: MOZOBIL: Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=112, Completed, Sponsor: Intergroupe Francophone du Myelome
- carfilzomib / Generic mfg.
Clinical: CARAMEL 2: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (clinicaltrials.gov) - Dec 19, 2016
P2, N=0, Withdrawn, Sponsor: Mayo Clinic
Active, not recruiting --> Completed N=43 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Sep 2014
- fidanacogene elaparvovec (PF-06838435) / Pfizer
Enrollment change, Trial termination, Trial primary completion date, Gene therapy, Viral vector: Hemophilia B Gene Therapy With AAV8 Vector (clinicaltrials.gov) - Dec 19, 2016
P1/2, N=4, Terminated, Sponsor: Spark Therapeutics
N=43 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Sep 2014 N=15 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2016
- | Xyntha (moroctocog alfa) / Pfizer
Phase classification: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Dec 15, 2016
P4, N=120, Active, not recruiting, Sponsor: Pfizer
N=15 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2016 Phase classification: P=N/A --> P4
- Trial completion: HEPS: An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia (clinicaltrials.gov) - Dec 14, 2016
P=N/A, N=66, Completed, Sponsor: The Hospital for Sick Children
Phase classification: P=N/A --> P4 Active, not recruiting --> Completed
- | arsenic trioxide / Generic mfg.
Trial completion: Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 14, 2016
P1/2, N=22, Completed, Sponsor: University of Miami
Active, not recruiting --> Completed No longer recruiting --> Completed
- GO-203-2c / Genus Oncology
Enrollment change, Trial withdrawal, Combination therapy: GO-203-2C + Bortezomib For Relapsed Or Refractory MM (clinicaltrials.gov) - Dec 13, 2016
P1, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
No longer recruiting --> Completed N=28 --> 0 | Not yet recruiting --> Withdrawn
- bortezomib / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients (clinicaltrials.gov) - Dec 12, 2016
P2, N=8, Terminated, Sponsor: University of Utah
N=28 --> 0 | Not yet recruiting --> Withdrawn N=10 --> 8 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Apr 2015; Slow Accrual
- Enrollment closed, Enrollment change, Metastases: Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer (clinicaltrials.gov) - Dec 8, 2016
P2, N=11, Active, not recruiting, Sponsor: University of Arizona
N=10 --> 8 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Apr 2015; Slow Accrual Recruiting --> Active, not recruiting | N=20 --> 11
- Enrollment closed, Enrollment change, Trial primary completion date: Total Marrow Irradiation for Refractory Acute Leukemia (clinicaltrials.gov) - Dec 8, 2016
P1, N=12, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting | N=20 --> 11 Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Sep 2017 --> Feb 2016
- ||||| Enrollment closed, Trial primary completion date: PETHEMA: Bortezomib (Velcade (clinicaltrials.gov) - Dec 8, 2016
P3, N=460, Active, not recruiting, Sponsor: PETHEMA Foundation
Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Sep 2017 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Oct 2015
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Dec 8, 2016
P1, N=16, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Oct 2015 Recruiting --> Active, not recruiting | N=22 --> 16 | Trial primary completion date: Dec 2016 --> Sep 2016
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg., clarithromycin / Generic mfg.
New P2 trial, Combination therapy: Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma (clinicaltrials.gov) - Dec 8, 2016
P2, N=60, Recruiting, Sponsor: Sun Yat-sen University
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg.
New P2 trial: Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 6, 2016
P2, N=30, Recruiting, Sponsor: Sun Yat-sen University
- Trial completion, Enrollment change, Trial primary completion date: Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions (clinicaltrials.gov) - Dec 2, 2016
P=N/A, N=44, Completed, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting | N=22 --> 16 | Trial primary completion date: Dec 2016 --> Sep 2016 Active, not recruiting --> Completed | N=250 --> 44 | Trial primary completion date: Jan 2017 --> Jul 2016
- Farydak (panobinostat) / Secura Bio
Clinical: Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 2, 2016
P1, N=22, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | N=250 --> 44 | Trial primary completion date: Jan 2017 --> Jul 2016 Trial primary completion date: Aug 2016 --> Feb 2016
- | roneparstat (LB401) / Leadiant Biosci
Trial completion, Enrollment change, Trial primary completion date, Metastases: SST0001 (Roneparstat) in Advanced Multiple Myeloma (clinicaltrials.gov) - Dec 2, 2016
P1, N=19, Completed, Sponsor: Sigma Tau Research Switzerland SA
Trial primary completion date: Aug 2016 --> Feb 2016 Recruiting --> Completed | N=30 --> 19 | Trial primary completion date: Mar 2017 --> Nov 2016
- NovoSeven (eptacog alfa) / Novo Nordisk
Enrollment closed: A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan (clinicaltrials.gov) - Dec 1, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | N=30 --> 19 | Trial primary completion date: Mar 2017 --> Nov 2016 Enrolling by invitation --> Active, not recruiting
- melphalan / Generic mfg.
Trial primary completion date: Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation (clinicaltrials.gov) - Dec 1, 2016
P2, N=24, Recruiting, Sponsor: Medical College of Wisconsin
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Oct 2016 --> Oct 2025
- Trial completion: Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 (clinicaltrials.gov) - Dec 1, 2016
P2, N=40, Completed, Sponsor: Centre Hospitalier Universitaire, Amiens
Trial primary completion date: Oct 2016 --> Oct 2025 Active, not recruiting --> Completed
- ||| New trial: Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass (clinicaltrials.gov) - Dec 1, 2016
P=N/A, N=60, Not yet recruiting, Sponsor: Ume
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment closed: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Nov 30, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Decadron (dexamethasone) / Merck (MSD)
Trial completion: A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) (clinicaltrials.gov) - Nov 30, 2016
P1, N=77, Completed, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - Nov 30, 2016
P3, N=40, Completed, Sponsor: Octapharma
No longer recruiting --> Completed Initiation date: Jun 2011 --> Oct 2011
- bortezomib / Generic mfg., lenalidomide / Generic mfg., sirolimus / Generic mfg.
Enrollment open, Trial primary completion date: EMN-alloRIC: Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (clinicaltrials.gov) - Nov 30, 2016
P2, N=45, Recruiting, Sponsor: European Myeloma Network
Initiation date: Jun 2011 --> Oct 2011 Completed --> Recruiting | Trial primary completion date: May 2016 --> Jun 2017
- New trial: MRA With Feraheme in HHT (clinicaltrials.gov) - Nov 30, 2016
P=N/A, N=10, Recruiting, Sponsor: University of California, Los Angeles
- || Ninlaro (ixazomib) / Takeda
Trial primary completion date, Combination therapy: Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 29, 2016
P1/2, N=164, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Completed --> Recruiting | Trial primary completion date: May 2016 --> Jun 2017 Trial primary completion date: Jan 2016 --> Dec 2016
- Ninlaro (ixazomib) / Takeda
Enrollment change: Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 29, 2016
P1, N=19, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Jan 2016 --> Dec 2016 N=43 --> 19
- ||||| Cablivi (caplacizumab) / Sanofi
Enrollment change: HERCULES: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Nov 29, 2016
P3, N=132, Recruiting, Sponsor: Ablynx
N=43 --> 19 N=92 --> 132
- lenalidomide / Generic mfg., thalidomide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) (clinicaltrials.gov) - Nov 28, 2016
P=N/A, N=10, Terminated, Sponsor: M.D. Anderson Cancer Center
N=92 --> 132 N=17 --> 10 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Nov 2016; Poor Response Rate
- bortezomib / Generic mfg.
Preclinical, Trial primary completion date: Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro (clinicaltrials.gov) - Nov 26, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
N=17 --> 10 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Nov 2016; Poor Response Rate Trial primary completion date: Oct 2016 --> Oct 2017
- GO-203-2c / Genus Oncology
Trial initiation date, Combination therapy: GO-203-2C + Bortezomib For Relapsed Or Refractory MM (clinicaltrials.gov) - Nov 25, 2016
P1, N=28, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Oct 2016 --> Oct 2017 Initiation date: Dec 2016 --> Jun 2017
- Jivi (damoctocog alfa pegol) / Bayer
New trial, Interview: Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A (clinicaltrials.gov) - Nov 23, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: Bayer